Team: Strategy and Operations

Home » Our Mission » Who We Are » Staff »
Amy Laverdiere
Amy Laverdiere

Amy Laverdiere

Program Lead for MDMA

Amy Laverdiere is the program lead for MDMA at MAPS Public Benefit Corporation. Amy has spent her career in many areas of drug and medical device development and commercialization. Prior to joining MAPS PBC, Amy was the program lead for PALFORZIA, the first FDA-approved therapy for peanut allergy, at Aimmune Therapeutics. She previously worked in process development at Genzyme and Genentech, in finance at Hatteras Venture partners, and held various marketing and commercial development roles at Medtronic and Cytokinetics. Amy holds a bachelor's degree in chemical engineering from the Massachusetts Institute of Technology and an MBA from Duke University's Fuqua School of Business.

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
Contact Us
Privacy Policy

Cookie Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!